Abstract
Current dendritic cell (DC) vaccine preparations involving ex vivo differentiation and maturation produce short-lived, transiently active DCs that may curtail T-cell responses in vivo. We demonstrate that Akt1, downregulation of which decreases DC lifespan, is critical for proinflammatory signal–mediated DC survival and maturation. Lipopolysaccharide or CD40 signaling stabilizes Akt1, promoting both activation and Bcl-2–dependent survival of DCs. Expression of a potent allele encoding a lipid raft–targeted Akt1, MF-ΔAkt, is sufficient for maturation and survival of murine bone marrow–derived DCs in vivo. MF-ΔAkt–transduced DCs enhanced T-cell proliferation, activation and long-term memory responses, enabling eradication of large pre-established lymphomas and aggressive B16 melanomas. Human myeloid DCs expressing constitutively active MF-ΔhAkt also survived significantly longer and promoted antigen-specific T-cell responses. Thus, Akt1 is a critical regulator of DC lifespan, and its manipulation in DCs can improve the clinical efficacy of DC-based tumor vaccines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schuler, G., Schuler-Thurner, B. & Steinman, R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138–147 (2003).
Ridgway, D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21, 873–886 (2003).
Hermans, I.F., Ritchie, D.S., Yang, J., Roberts, J.M. & Ronchese, F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164, 3095–3101 (2000).
Liu, K. et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091–1097 (2002).
Park, Y., Lee, S.W. & Sung, Y.C. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J. Immunol. 168, 5–8 (2002).
Josien, R. et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191, 495–502 (2000).
Miga, A.J. et al. Dendritic cell longevity and T cell persistence is controlled by CD154–CD40 interactions. Eur. J. Immunol. 31, 959–965 (2001).
Nopora, A. & Brocker, T. Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169, 3006–3014 (2002).
Ouaaz, F., Arron, J., Zheng, Y., Choi, Y. & Beg, A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16, 257–270 (2002).
Contin, C. et al. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J. Biol. Chem. 278, 32801–32809 (2003).
Hanks, B.A. et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 11, 130–137 (2005).
Chuang, T.H. & Ulevitch, R.J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5, 495–502 (2004).
Wald, D. et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4, 920–927 (2003).
Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191–202 (2002).
Watanabe, T., Kitani, A., Murray, P.J. & Strober, W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5, 800–808 (2004).
Shen, L., Evel-Kabler, K., Strube, R. & Chen, S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 1546–1553 (2004).
Mansell, A. et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7, 148–155 (2006).
Hou, W.S. & Van Parijs, L.A. Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5, 583–589 (2004).
Brazil, D.P., Yang, Z.Z. & Hemmings, B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233–242 (2004).
Ishii, K.J. et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196, 269–274 (2002).
Ardeshna, K.M., Pizzey, A.R., Devereux, S. & Khwaja, A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96, 1039–1046 (2000).
Bharti, A.C. & Aggarwal, B.B. Ranking the role of RANK ligand in apoptosis. Apoptosis 9, 677–690 (2004).
Yu, Q., Kovacs, C., Yue, F.Y. & Ostrowski, M.A. The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J. Immunol. 172, 6047–6056 (2004).
Vassiliou, E., Sharma, V., Jing, H., Sheibanie, F. & Ganea, D. Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J. Immunol. 173, 6955–6964 (2004).
Kanto, T., Kalinski, P., Hunter, O.C., Lotze, M.T. & Amoscato, A.A. Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167, 3773–3784 (2001).
Mochizuki, T. et al. Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide. J. Biol. Chem. 277, 2790–2797 (2002).
Guha, M. et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98, 1429–1439 (2001).
Okugawa, S. et al. Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. Am. J. Physiol. Cell Physiol. 285, C399–C408 (2003).
Napolitani, G., Bortoletto, N., Racioppi, L., Lanzavecchia, A. & D'Oro, U. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur. J. Immunol. 33, 2832–2841 (2003).
Woltman, A.M. et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101, 1439–1445 (2003).
Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882–888 (2001).
Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249–1255 (1999).
Katome, T. et al. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J. Biol. Chem. 278, 28312–28323 (2003).
Arbibe, L. et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat. Immunol. 1, 533–540 (2000).
Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349–16354 (1999).
Mukherjee, A., Arnaud, L. & Cooper, J.A. Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain. J. Biol. Chem. 278, 40806–40814 (2003).
Li, B., Desai, S.A., MacCorkle-Chosnek, R.A., Fan, L. & Spencer, D.M. A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis. Gene Ther. 9, 233–244 (2002).
Sporri, R. & Reis e Sousa, C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6, 163–170 (2005).
van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481–489 (2001).
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769–776 (2005).
Jonuleit, H. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135–3142 (1997).
Xu, J., Liu, D. & Songyang, Z. The role of Asp-462 in regulating Akt activity. J. Biol. Chem. 277, 35561–35566 (2002).
Riesterer, O., Zingg, D., Hummerjohann, J., Bodis, S. & Pruschy, M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 23, 4624–4635 (2004).
Fukao, T. et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875–881 (2002).
Martin, M., Rehani, K., Jope, R.S. & Michalek, S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777–784 (2005).
Del Prete, A. et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J. 23, 3505–3515 (2004).
Beutler, B. & Rietschel, E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3, 169–176 (2003).
Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5, 1313–1316 (1999).
Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693–1702 (1992).
Nikitina, E.Y. et al. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 65, 4309–4319 (2005).
Acknowledgements
We are grateful to B.A. Hanks, E.Yu. Nikitina, Rama Gangula, J. Lim, S. Nam and M. Kim for advice and technical assistance, C.M. Rooney, E.Yu. Nikitina and D. Lewis for a critical reading of the manuscript and to K. Walsh for providing the recombinant adenovirus encoding constitutively active Akt (Ad-M-Akt). This work was supported by Department of Defense grant no. DAMD17-03-1-0156 and generous donations from the Baylor College of Medicine Prostate Cancer Research Initiative (PCRI).
Author information
Authors and Affiliations
Contributions
D.P. designed and performed most of the experiments and co-wrote the paper; N.L. performed most of the human DC experiments (Fig. 6); M.S. provided technical support for plasmid preparation, mouse breeding and tumor measurement, K.M.S. advised on the study; D.M.S. co-designed the study, advised on experiments and co-wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Role of Akt-1 in DC survival. (PDF 198 kb)
Supplementary Fig. 2
Analysis of surface markers of Akt1+/+ or Akt1−/− DCs. (PDF 870 kb)
Supplementary Fig. 3
Development of improved constitutive Akt1. (PDF 1054 kb)
Supplementary Fig. 4
Treatment of subcutaneous tumors with MF-ΔAkt-DCs. (PDF 870 kb)
Supplementary Fig. 5
Vaccination with MF-ΔAkt-DCs leads to antigen-specific memory. (PDF 132 kb)
Supplementary Fig. 6
Enhanced efficacy of MF-ΔhAkt-MoDCs. (PDF 379 kb)
Rights and permissions
About this article
Cite this article
Park, D., Lapteva, N., Seethammagari, M. et al. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 24, 1581–1590 (2006). https://doi.org/10.1038/nbt1262
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1262
This article is cited by
-
Association between the AKT1 single nucleotide polymorphism (rs2498786, rs2494752 and rs5811155) and microscopic polyangiitis risk in a Chinese population
Molecular Genetics and Genomics (2023)
-
Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model
Scientific Reports (2020)
-
Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses
Journal of Neuroinflammation (2019)
-
Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity
Journal of Experimental & Clinical Cancer Research (2019)
-
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
Leukemia (2018)